Thank You - Omico

Industry
Researchers
Clinicians
Patients & Families
Advocacy Groups
PrOSPeCT
Our Programs
- - - PROGRAMS
    - Cancer Screening Program (CaSP)
    - Bringing comprehensive genomic profiling to patients with advanced and incurable cancer
    - Molecular Screening and Therapeutics (MoST) study
    - Using the power of genomic technology to characterise molecular changes in a patient's cancer
    - Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+)
    - Investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer
    - Genetic Cancer Risk in the Young (RisC) study – Now closed
    - Understanding the genetic variants that contribute to inherited cancer
  - - CLINICAL TRIALS
    - Company Studies (C3)
    - Companion Studies (C2)
    - MoST Core Studies (C1)
    - MoST-LLy
    - ASPiRATION
Resources & Events
About Us
News
Contact

Partner Toolkits
Resources & Events
About Us
News
Contact

Sign up for newsletter

Thank you

Thank you for signing up to Omico’s newsletter. We look forward to keeping you informed.

Privacy Policy
Omico is registered not-for-profit company
Site Map